(Total Views: 495)
Posted On: 08/12/2019 12:56:04 PM
Post# of 72446
"There should be no shortage of biotech companies looking to file an IPO — or execute a buyout deal — in 2020 and 2021.
Michael Yee’s team at Jefferies gathered the numbers for the last few years and tracked the tens of billions in cash that is being pumped into biotech startups. A few salient points emerge:
Annual venture funding in life sciences has grown from the $8-to-$10 billion range 5 years ago to the $20-to-$30 billion range today.
In just two years, the average number of venture rounds per quarter has doubled — growing from 20-30 every 3 months in 2017 to 40 to 60. And there have been 18 rounds of more than $100 million so far this year.
That all sets up an even more heated comparison of the newly effervescent M&A market for startups compared to the search for public investors — a trend that has fueled a much larger migration to commercialization work among small and mid-cap biotechs. And it’s all playing out in the short term during an unprecedented bull market for biotech."
Michael Yee’s team at Jefferies gathered the numbers for the last few years and tracked the tens of billions in cash that is being pumped into biotech startups. A few salient points emerge:
Annual venture funding in life sciences has grown from the $8-to-$10 billion range 5 years ago to the $20-to-$30 billion range today.
In just two years, the average number of venture rounds per quarter has doubled — growing from 20-30 every 3 months in 2017 to 40 to 60. And there have been 18 rounds of more than $100 million so far this year.
That all sets up an even more heated comparison of the newly effervescent M&A market for startups compared to the search for public investors — a trend that has fueled a much larger migration to commercialization work among small and mid-cap biotechs. And it’s all playing out in the short term during an unprecedented bull market for biotech."
(7)
(1)
